Page last updated: 2024-09-04

docetaxel anhydrous and Cancer of Esophagus

docetaxel anhydrous has been researched along with Cancer of Esophagus in 426 studies

Research

Studies (426)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (0.94)	18.2507
2000's	81 (19.01)	29.6817
2010's	267 (62.68)	24.3611
2020's	74 (17.37)	2.80

Authors

Authors	Studies
Bhagia, P; Doi, T; Han, S; Ishihara, R; Iwakami, K; Kato, K; Kawakami, H; Kojima, T; Moriwaki, T; Muro, K; Nagashima, F; Ogata, T; Satoh, T; Takami, T; Yatsuzuka, N	1
Bo, C; Dong, L; Guo, L; Guo, Y; He, L; Zhang, S; Zhang, Y; Zheng, Z	1
Baba, H; Emi, Y; Hamai, Y; Hihara, J; Kitagawa, Y; Kunisaki, C; Maehara, Y; Matsubara, H; Morita, S; Nagano, H; Nakashima, Y; Oki, E; Otsuji, E; Saeki, H; Takeuchi, H; Tanaka, Y; Tomizuka, K; Ueno, T; Yoshida, K	1
Hazarika, M; Kumar, G; Mallik, S; Roy, PS; Saikia, BJ; Sarangi, SS; Talukdar, A	1
Chang, DD; Feng, ST; Guo, QK; Lei, YY; Li, HJ; Liu, LZ; Xu, BC; Xu, M; Yan, J; Yao, W; Zhu, Y; Zhu, ZH	1
Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM	1
Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Nomura, H; Tsuji, D; Ueno, S; Yano, T	1
Bao, Y; Cai, J; Chen, J; Chen, M; Dong, B; Du, X; Guan, N; He, H; Hu, J; Hu, W; Huang, J; Huang, R; Jiang, H; Kong, Y; Li, J; Liang, X; Liao, Z; Liu, L; Liu, Y; Liu, Z; Ma, J; Pu, J; Qiu, G; Sun, Z; Tao, G; Tao, H; Wang, W; Xu, Y; Yang, X; Zeng, M; Zheng, X; Zhou, J; Zhu, W; Zhuang, T	1
Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D	1
Akaishi, R; Ando, R; Fukutomi, T; Horie, Y; Kamei, T; Okamoto, H; Ozawa, Y; Sato, C; Shinozaki, Y; Takahashi, K; Taniyama, Y; Unno, M	1
Ajani, JA; Arkenau, HT; Bi, Q; Borg, C; Chen, J; Chen, Z; Ding, N; Hara, H; He, Z; Kato, K; Kim, SB; Li, L; Lin, CY; Lordick, F; Luo, Q; Niu, Z; Pazo-Cid, R; Satoh, T; Shen, L; Shi, J; Shu, Y; Sun, JM; Tao, A; Van Cutsem, E; Wang, J; Yi, T; Yu, G; Yu, X; Zhang, L; Zhao, K	1
Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Ninomiya, I; Okamoto, K; Saito, H; Shimada, M; Terai, S; Yamaguchi, T	1
Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB	1
Asadi, J; Jafari, SM; Mohammadi, Z	1
Bartels, A; Brossart, P; Feldmann, G; Giordano, FA; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, M; Sadeghlar, F; Sarria, GR; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T	1
Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S	1
Fujiwara, T; Hashimoto, M; Kunitomo, T; Maeda, N; Nishiwaki, N; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S	1
Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M	3
Chen, J; Chen, Y; Lin, YT; Liu, TX; Wang, C	1
Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y	1
Gabata, T; Kozaka, K; Sai, Y; Takamatsu, A; Toshima, F; Yamamoto, N; Yoshida, K	1
Akita, H; Fujii, Y; Hara, H; Haraguchi, N; Hasegawa, S; Kanemura, T; Matsuda, C; Mikamori, M; Miyata, H; Mukai, Y; Nishimura, J; Omori, T; Shinno, N; Sugase, T; Sugimura, K; Takeoka, T; Wada, H; Yamamoto, M; Yasui, M	1
Chan, KK; Chan, SY; Chan, WL; Cheung, EE; Choi, CW; Kwong, D; Lam, AT; Lam, KO; Law, BT; Law, S; Tsang, TH; Tse, RP; Wong, C; Wong, IY	1
Jia, SJ; Liu, Q; Song, LY; Wang, C; Zeng, H; Zeng, X	1
Chin, K; Doki, Y; Fujitani, K; Fushiki, K; Hironaka, S; Kato, K; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Okuno, T; Seki, S; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T	1
Inagaki, T; Kin, M; Kogo, M; Murakami, M; Otsuka, K; Sato, M	1
Chiba, Y; Haratani, K; Hayashi, H; Kanemura, H; Kawakami, H; Mitani, S; Nakagawa, K; Shiraishi, O; Suzuki, S; Yasuda, T; Yonesaka, K	1
Amanuma, Y; Arimitsu, Y; Chin, K; Kadowaki, S; Kanda, M; Kimura, Y; Kitagawa, Y; Kubota, Y; Nogi, Y; Okada, M; Takahashi, M; Yamamoto, S	1
Daiko, H; Honma, Y; Ishiyama, K; Kanematsu, K; Kato, K; Kubo, K; Kurita, D; Oguma, J; Utsunomiya, D; Yamamoto, S	1
Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T	1
Akimoto, S; Fujita, M; Goto, A; Inaba, K; Matsuoka, H; Nakamura, K; Nakauchi, M; Serizawa, A; Shibasaki, S; Suda, K; Tanaka, T; Umeki, Y; Uyama, I	1
Kawasaki, K; Nara, K; Sato, Y; Seto, Y; Suzuki, H; Takada, T; Toriumi, T; Yagi, K; Yamamoto, T	1
Bruckner, T; Büchler, MW; Crnovrsanin, N; Haag, GM; Jung, JO; Müller-Stich, BP; Nienhueser, H; Schiefer, S; Schmidt, T; Schneider, M; Sisic, L	1
Ebata, T; Fukaya, M; Miyata, K; Shimizu, D; Sugita, S	1
Ihara, K; Inoue, N; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T	1
Haruki, S; Miura, A; Sasaki, N; Suzuki, K; Yamaguchi, K	1
Eto, K; Kurogochi, T; Matsumoto, A; Nakayoshi, T; Nyumura, Y; Okamoto, T; Tanishima, Y; Yano, F	1
Hirabayashi, T; Kushida, S; Miki, I; Mimura, T; Nishikawa, M; Takegawa, N; Tanaka, S; Tokuyama, N; Tsuda, M; Tsumura, H; Yamamoto, Y	1
Mehta, R; Shariff, B	1
Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y	1
Daiko, H; Hara, H; Hori, K; Kadota, T; Kato, K; Kitagawa, Y; Mizusawa, J; Ogata, T; Ogawa, H; Sakamoto, T; Sakanaka, K; Terada, M	1
Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M	1
Asukai, K; Hasegawa, S; Miyata, H; Motoori, M; Nishimura, J; Ohue, M; Omori, T; Shinno, N; Sugimura, K; Takahashi, H; Takahashi, Y; Ushigome, H; Wada, H; Yamada, D; Yamamoto, K; Yanagimoto, Y; Yano, M; Yasui, M	1
Kawamoto, T; Kosugi, Y; Oshima, M; Sasai, K; Shikama, N; Tsurumaru, M	1
Arai, K; Fujinaka, R; Kakinoki, K; Kuroda, D; Mani, M; Mii, Y; Murata, K; Oka, S; Okamoto, S; Otowa, Y	1
Ajani, JA; Amini, A; Barsoumian, HB; Bhutani, MS; Blum, MA; Chang, JY; Chen, D; Erasmus, JJ; Gomez, DR; Hess, KR; Hofstetter, WL; Lee, JH; Menon, H; Minsky, BD; Nguyen, QN; Seyedin, SN; Swisher, SG; Verma, V; Welsh, JW; Younes, AI	1
Dohi, O; Fujiwara, H; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Shiozaki, A; Takagi, T; Teramukai, S; Uchiyama, K; Yasuda, T; Yoshida, N	1
Bugano, DDG; Maluf, FC; Rother, ET; Santos, VM; Uson Junior, PLS; Victor, EDS	1
Hamasu, S; Ikeda, Y; Konishi, S; Kudo, R; Manaka, D; Nishitai, R; Ota, T	1
Calomino, N; Cherri, S; Farsi, M; Fiaschi, AI; Francini, E; Francini, G; Marrelli, D; Miano, ST; Petrioli, R; Rovello, F; Savelli, V; Vernillo, R	1
Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S	1
Herrmann, K; Lordick, F	1
Ackland, SP; Barbour, AP; Barnes, EH; Burge, M; Falk, GL; Finch, R; Gebski, V; Karapetis, CS; Lampe, G; Mai, GT; Martin, JM; Marx, G; Nott, LM; Oostendorp, M; Shannon, J; Simes, J; Smithers, BM; Thomas, J; Varma, S; Walpole, ET; Watson, DI; Wilson, K; Zalcberg, JR	1
Hui, H; Sun, Y; Wei, B; Wu, J; Xu, L	1
Hanyu, T; Hirose, Y; Ichikawa, H; Ishikawa, T; Kameyama, H; Kano, Y; Kobayashi, T; Miura, K; Motegi, D; Nagahashi, M; Sakai, T; Sakata, J; Shimada, Y; Usui, K; Wakai, T	1
Kawamoto, T; Mine, S; Sasai, K; Shikama, N; Tsurumaru, M	1
Ajani, JA; Bhutani, MS; Huo, L; Jin, J; Johnson, RL; Lee, JH; Li, Y; Ma, L; Pool Pizzi, M; Scott, AW; Shanbhag, ND; Song, S; Wang, Y; Weston, B; Xu, Y	1
Chen, Y; Deng, J; Liu, Q; Xia, Y; Zhang, J; Zhao, K	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Abe, T; Aoki, K; Daiko, H; Hara, H; Kato, K; Kitagawa, Y; Kitano, S; Kojima, T; Mizoguchi, Y; Nagashima, K; Shiba, S; Tsubosa, Y; Yachida, S; Yamamoto, S	1
Baba, Y; Egashira, A; Emi, Y; Fujiwara, M; Iwata, N; Jogo, T; Kamori, T; Kawazoe, T; Kimura, Y; Makiyama, A; Mori, M; Morita, M; Nakaji, Y; Nakamura, T; Nakanoko, T; Nakashima, Y; Oki, E; Saeki, H; Shibata, T; Shimokawa, M; Tanaka, Y; Tokunaga, S; Zaitsu, Y	1
Adachi, T; Eguchi, S; Hidaka, M; Inoue, Y; Isagawa, Y; Ito, S; Kanetaka, K; Kawaguchi, Y; Kobayashi, K; Kobayashi, S; Kosaka, T; Kuba, S; Maruya, Y; Migita, K; Morita, M; Okada, S; Takatsuki, M; Torashima, Y; Yamaguchi, S; Yoneda, A; Yoshimoto, T	1
Abraham, P; Gricar, J; Shankaran, V; Zhang, Y	1
Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC	1
Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T	1
Abe, T; Bando, H; Higaki, E; Hosoi, T; Kadowaki, S; Muro, K; Nagao, T; Niwa, Y; Shimizu, Y; Tajika, M; Tanaka, T	1
Arakawa, Y; Matsumoto, A; Mitsumori, N; Nishikawa, K; Tanaka, Y; Tanishima, Y; Yanaga, K; Yuda, M	1
Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R	1
Alesina, P; Bartsch, D; Függer, R; Furrer, M; Gérard, MA; Gloor, B; Grieder, F; Hawle, H; Hayoz, S; Kettelhack, C; Knoefel, WT; Köigsrainer, A; Marti, WR; Piessen, G; Ruhstaller, T; Schäfer, M; Schmidt, S; Schnider, A; Steffen, T; von Holzen, U; Walz, MK	1
Deng, L; Feng, L; Guo, R; Li, Y; Liu, Z; Qin, L; Yu, Z; Zheng, Y; Zhu, X	1
Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A	1
Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A	1
Cai, B; Di, X; Ge, X; Liu, Z; Sun, X; Xia, X	1
Ajani, JA; Bhutani, M; Chen, Q; Correa, A; Estrella, JS; Gan, B; Hofstetter, WL; Huo, L; Jin, J; Johnson, RL; Lee, JH; Lei, G; Li, CY; Li, Y; Liu, B; Ma, L; Pizzi, MP; Scott, A; Shanbhag, N; Song, S; Wang, Y; Wei, S; Weston, B; Xiao, L	1
Gao, Y; Jiang, C; Wang, T; Wei, B; Wu, J; Zhou, Y	1
Engel, J; Fagbemi, SO; Li, YH; Onitilo, AA; Shiyanbola, O; Stankowski-Drengler, TJ; Tanimu, S	1
Chen, Y; Gou, H; Hu, J; Leng, W; Ni, L; Qiu, M; Zhang, W	1
Cai, L; Hu, Y; Li, Q; Liu, H; Liu, M; Liu, S; Luo, L; Qiu, B; Shen, J; Xi, M; Yang, Y; Zhang, L; Zhao, L; Zhu, Y	1
Chen, W; Gu, D; Lu, J; Tao, H; Yao, C; Zhou, Y	1
Antoun, J; Arej, N; Chelala, E; El Karak, F; Farhat, F; Haddad, FG; Kattan, J; Kourie, HR; Zaarour, K	1
Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T	1
Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P	1
Bruns, CJ; Schröder, W	1
Akita, H; Fujiwara, Y; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Ohue, M; Omori, T; Sugimura, K; Takahashi, H; Tomokuni, A; Yanagimoto, Y; Yano, M; Yasui, M	1
Ding, XZ; Gao, SG; Hu, XC; Izumiya, Y; Kong, DJ; Lam, KS; Li, XC; Li, YP; Lin, TY; Wang, XS; Yang, JQ; Zhang, L	1
Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y	1
Al, MJ; Armstrong, N; Blommestein, HM; Büyükkaramikli, NC; Clay, FJ; Kleijnen, J; Riemsma, R; Ross, J; Severens, J; Worthy, G	1
Akiyama, Y; Chiba, T; Endo, F; Iwaya, T; Kimura, Y; Koeda, K; Mizuno, M; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T	1
Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakatani, M; Obayashi, C; Sho, M; Takano, M; Wakatsuki, K	1
Hamamoto, Y; Ito, Y; Kato, H; Kato, K; Kitagawa, Y; Kuroki, Y; Miyata, Y; Nozaki, I; Ogawa, H; Sato, H; Tsubosa, Y; Yasuda, T; Yokota, T	1
Du, N; Li, X; Liang, R; Liu, J; Pang, Y; Ren, H; Sun, X; Tang, SC; Xu, C; Zhang, B; Zhang, J; Zhang, Y	1
Etoh, T; Fujishima, H; Fumoto, S; Inomata, M; Moriyama, M; Nishiki, K; Shibata, T; Shiraishi, N; Tsukamoto, Y	1
Cartwright, E; Cunningham, D	1
Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Wada, N; Yamasaki, M	1
Ihara, K; Kato, H; Kikuchi, M; Kurayama, E; Kuwano, H; Miyazaki, T; Muroi, H; Nakajima, M; Ogata, H; Sakai, M; Sasaki, K; Shida, Y; Sohda, M; Takahashi, M; Yamaguchi, S	1
Fujiwara, T; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Noma, K; Shirakawa, Y; Tanabe, S	1
Hiwatashi, K; Maenohara, S; Minami, K; Natsugoe, S; Okumura, H; Omoto, I; Sasaki, K; Setoyama, T; Tsuruda, Y; Uchikado, Y	1
Kobayashi, K; Miki, H; Okada, K; Takeoka, T	1
Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Naito, A; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S	1
Arita, T; Fujiwara, H; Hikami, S; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Okamoto, K; Otsuji, E; Shiozaki, A	1
Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T	1
Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Odagiri, K; Takahashi, T; Tanaka, K; Yamazaki, M	1
Carter, BW; Goense, L; Ho, L; Hofstetter, WL; Lin, SH; Maru, DM; Meijer, GJ; van Hillegersberg, R; van Rossum, PSN; Xi, M	1
Bedenne, L; Bitzer, M; Brauchli, P; Budach, W; Eisterer, W; Girschikofsky, M; Hawle, H; Hayoz, S; Hess, V; Knorrenschild, JR; Mariette, C; Mingrone, W; Montemurro, M; Plasswilm, L; Ruhstaller, T; Schacher, S; Schmidt, SC; Schnider, A; Stahl, M; Thuss-Patience, P	1
Arava, S; Gogia, A; Kumar, R; Kumar, S; Tripathi, M	1
Hayata, K; Katsuda, M; Maruoka, S; Nakamori, M; Nakamura, M; Ojima, T; Shimokawa, T; Yamaue, H	1
Cannita, K; Cortellini, A; De Berardis, B; Ficorella, C; Lanfiuti Baldi, P; Parisi, A; Porzio, G; Venditti, O; Verna, L; Vicentini, R; Vicentini, V	1
Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J	1
Akiyama, Y; Amano, S; Baba, S; Chiba, T; Endo, F; Iwaya, T; Kimura, T; Kimura, Y; Koeda, K; Mizuno, M; Nikai, H; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T; Umemura, A	1
Ding, XZ; Gao, SG; He, Y; Hu, XC; Kong, DJ; Li, XC; Li, Y; Lin, TY; Wang, XS; Yang, JQ; Zhang, L; Zhao, MQ	1
Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T	1
Aoki, M; Komori, K; Sandou, M; Takagi, M; Uejima, E; Yoshida, Y	1
Dohi, O; Doi, T; Fujiwara, H; Handa, O; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Ohta, T; Okayama, T; Shiozaki, A; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, J; Yoshida, N	1
Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Terai, S; Yamaguchi, T	1
Hu, Y; Huang, C; Li, Q; Liu, H; Liu, M; Yuan, Y; Zhang, W; Zhu, Y	1
Chikugo, T; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kawakami, H; Kimura, Y; Nakagawa, K; Okuno, T; Shinkai, M; Shiraishi, O; Ueda, H; Yasuda, A; Yasuda, T	1
Fushida, S; Gabata, R; Gunjigake, K; Ninomiya, I; Ohta, T; Okamoto, K; Yamaguchi, T	1
Fukuda, K; Irino, T; Kawakubo, H; Kitagawa, Y; Mayanagi, S; Nakamura, R; Takeuchi, H; Takeuchi, M; Wada, N; Yoshida, K	1
Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M	1
Baba, H; Baba, Y; Harada, K; Imai, K; Imamura, Y; Ishimoto, T; Iwatsuki, M; Karashima, R; Koga, Y; Nagai, Y; Nomoto, D; Okadome, K; Watanabe, M; Yoshida, N	1
Dohi, O; Doi, T; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Ota, T; Sakamoto, N; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, J; Yoshida, N	1
Kazuno, A; Koyanagi, K; Ninomiya, Y; Oguma, J; Ozawa, S; Yamamoto, M; Yatabe, K	1
Cao, F; Chen, X; Cheng, J; Er, P; Guan, Y; Jiang, H; Li, X; Pang, Q; Qian, D; Wang, J; Wang, P; Wang, Y; Yu, Z; Yuan, Z; Zhang, B; Zhang, W; Zhao, G; Zhou, D	1
Akiyama, Y; Baba, S; Chiba, T; Endo, F; Iwaya, T; Kimura, T; Kimura, Y; Koeda, K; Mizuno, M; Nikai, H; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T	1
Ohkura, Y; Udagawa, H; Ueno, M	1
Daiko, H; Hatogai, K; Kawasaki, T; Kojima, T; Maki, Y; Mochizuki, N; Nomura, H; Saito, S; Tanaka, M	1
Akutsu, Y; Chin, K; Hamamoto, Y; Hara, H; Hironaka, S; Ito, Y; Kato, K; Kawakami, K; Kii, T; Kitagawa, Y; Kojima, T; Kojima, Y; Makiuchi, T; Matsushita, H; Mori, K; Nagumo, R; Ogawa, H; Tsubosa, Y; Ura, T; Yokota, T	1
Cardic, MB; Chao, Y; Chen, LT; Cunningham, D; de Gramont, A; Kang, YK; Kujundzic, M; Lim, HY; Park, SR; Ramos, FJ; Rees, C; Roy, AC; Tabernero, J; Yeh, CG	1
Akutsu, Y; Hoshino, I; Kono, T; Matsubara, H; Miyazawa, Y; Shiratori, T; Shuto, K; Takeshita, N; Uesato, M	1
Dobrovic, A; Ganju, V; Gebski, VJ; Mellor, D; Parry, MM; Pavlakis, N; Strickland, AH; Tebbutt, NC; Van Hazel, GA; Zannino, D	1
Al-Batran, SE; Hartmann, JT; Hofheinz, RD; Homann, N; Kripp, M; Moehler, M; Pauligk, C; Rosowski, J	1
Huang, XE; Liu, J; Lu, YY; Shen, K; Wu, XY; Xiang, J	1
Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P	1
Ando, N; Daiko, H; Fukuda, H; Hironaka, S; Igaki, H; Ito, Y; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Tsubosa, Y; Udagawa, H	1
Asmar, L; Cohn, A; David McCollum, A; Diab, S; Hecker, LI; Kocs, DM; Richards, D; Spira, AI; Zhan, F	1
Jeong, S; Ki, SH; Kim, HG; Kwon, KS; Lee, DH; Lee, JI; Park, IS; Shin, YW	1
Doki, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Sugimura, K; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M	1
Fujiwara, H; Furukawa, T; Furukita, Y; Goto, M; Ikeda, M; Morimoto, M; Nishino, T; Seike, J; Takechi, H; Tangoku, A; Yamamoto, Y	1
Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH	1
Arita, K; Bhunachet, E; Haruki, S; Hiranuma, S; Ito, K; Matsumoto, A; Takiguchi, N; Usui, S	1
Daiko, H; Hamamoto, Y; Hara, H; Hosoya, Y; Igaki, H; Kadowaki, S; Kato, K; Matsushita, H; Nagase, M; Tahara, M; Tanaka, Y	1
Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH	1
Arnold, D; Geissler, M; Grothe, W; Hofheinz, RD; Moehler, M; Reinacher-Schick, A; Schmoll, HJ; Seufferlein, T; Stein, A; Thuss-Patience, PC	1
Ji, FZ; Li, T; Pan, P; Tao, GZ; Yu, CH; Zhou, XL; Zhu, WG	1
Li, X; Lin, S; Lin, W; Lin, Y; Wang, H	1
Arena, MG; Barba, M; Belli, F; Di Lauro, L; Fattoruso, SI; Giannarelli, D; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, S; Vici, P	1
Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Minemura, M; Nishikawa, J; Ogawa, K; Sugiyama, T; Ueda, A; Ueda, Y; Yoshita, H	1
Park, SH	1
Blazeby, JM; Bridgewater, JA; Chau, I; Cook, N; Coxon, FY; Cunningham, D; Dunn, JA; Falk, S; Ford, HE; Fyfe, D; Janowitz, T; Kareclas, P; Madhusudan, S; Mansoor, W; Marshall, A; Middleton, GW; Swinson, D; Wadsley, J	1
Fujiwara, T; Katsube, R; Maeda, N; Noma, K; Ohara, T; Sakurama, K; Shirakawa, Y; Tanabe, S	1
Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Nishiya, S; Okubo, Y; Sato, S	1
Asaka, S; Endo, M; Katsube, T; Miyaki, A; Murayama, M; Naitou, E; Naritaka, Y; Shimakawa, T; Shimazaki, A; Shiozawa, S; Usuda, A; Yamaguchi, K; Yokomizo, H; Yoshimatsu, K	1
Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G	1
Battafarano, RJ; Burrows, WM; Edelman, MJ; Hanlon, AL; Horiba, MN; Kim, GJ; Koshy, M; Suntharalingam, M	1
Ban, X; Cai, Z; Cao, TT; Chen, J; Fu, L; Guan, XY; Huang, P; Li, JB; Li, Y; Qian, C; Qin, Y; Xie, D; Zeng, TT; Zeng, ZL; Zhou, J	1
Cassivi, SD; Decker, PA; Ferguson, MK; Lockhart, AC; Meyers, BF; Montero, AJ; Oeltjen, AR; Putnam, JB; Reed, CE; Schefter, TE	1
Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N	1
Cha, J; Kim, SK; Koom, WS; Lee, CG; Lee, IJ; Lee, JY; Suh, YG	1
Baba, H; Baba, Y; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N	1
Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S	1
Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J	1
Haruma, K; Higashida, M; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Nakamura, M; Yoden, E	1
Ades, S; Alcindor, T; Aloraini, A; Asselah, J; Brisson, S; David, M; Ferri, L; Frechette, D; Sudarshan, M; Thirlwell, M; van Huyse, M	1
Cai, XY; Chen, XX; Guo, GF; He, WZ; Jiang, C; Liao, FX; Qiu, HJ; Rong, YM; Xia, LP; Yang, Q; Yin, CX; Zhang, B	1
Chin, K; Doki, Y; Fujitani, K; Hironaka, S; Kato, K; Kii, T; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Nakamura, T; Okuno, T; Seki, S; Taira, K; Taniki, T; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T	1
Jambhekar, N; Jandyal, S; Joshi, A; Noronha, V; Prabhash, K	1
Deng, WY; Li, N; Li, X; Luo, SX; Song, T	1
Huang, ZJ; Lin, JQ; Xu, TW; Yang, N	1
Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M	2
Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N	1
Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y	1
Di, ZL; Ke, Y; Ma, HB; Ren, J; Sun, X; Wen, J	1
Alcindor, T; Asselah, J; Cools-Lartigue, J; Eckert, E; Ferri, LE; Jones, D; Rousseau, M; Spicer, J; Vanhuyse, M; Zourikian, T	1
Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T	2
Hosoda, K; Katada, N; Kikuchi, S; Mieno, H; Moriya, H; Sakuramoto, S; Watanabe, M; Yamashita, K	1
Domeki, Y; Kato, H; Murakami, M; Muroi, H; Nakajima, M; Nakamura, T; Satomura, H; Takada, A; Takahashi, M	1
Chin, K; Fukuda, H; Hironaka, S; Kataoka, K; Katayama, H; Kato, K; Kii, T; Kitagawa, Y; Mizusawa, J; Shibuya, Y; Tsubosa, Y; Tsushima, T	1
Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T	1
Fujita, H; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Miura, S; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Tomita, Y; Ueda, N	1
Bianco, V; Brozzetti, S; Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Rossi, G; Roviello, F; Roviello, G	1
Fujimura, T; Kitagawa, H; Makino, I; Maruzen, S; Nakamura, K; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Takamura, H	1
Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY	1
Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Nagata, Y; Okada, M	1
Chen, X; Gao, Y; Han, Q; Jin, Y; Qian, Z; Wan, L; Wei, B; Wu, J; Xu, L; Zhang, X; Zhou, J; Zhu, J	1
Choudhury, NR; Garg, S; Knott, R; Shaikh, M	1
Kawakami, H; Nakagawa, K; Nishina, S; Nonagase, Y; Okabe, T; Sakiyama, T; Tamura, T; Ueda, S	1
Abe, T; Andoh, M; Ishihara, M; Kadowaki, S; Kawai, R; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H; Uemura, N; Ura, T	1
Han, S; Liang, H; Liu, W; Wen, H; Yang, H; Yao, J; Yu, L	1
Liu, MZ; Liu, SL; Luo, LL; Wu, YJ; Xi, M; Yang, H; Yang, YD; Zhang, P; Zhao, L	1
Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R	1
Bronsert, P; Glatz, T; Hoeppner, J; Hopt, UT; Kulemann, B; Makowiec, F; Marjanovic, G; Schäfer, M; Sick, O; Zirlik, K	1
Bencivenga, M; Carbone, C; De Manzoni, G; Frizziero, M; Giacopuzzi, S; Melisi, D; Merz, V; Mina, MM; Piro, G; Santoro, R; Tortora, G; Verlato, G; Zanoni, A; Zanotto, M	1
Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y	1
Dunn, JA; Ford, HE; Hulme, CT; Marshall, A; Meads, DM	1
Domeki, Y; Ihara, K; Kato, H; Kikuchi, M; Kubo, T; Muroi, H; Nakajima, M; Otomo, H; Sasaki, K; Satomura, H; Takahashi, M; Yamaguchi, S	1
Aga, K; Harada, H; Kaburagi, T; Koizumi, W; Matsumoto, H; Sakata, M; Seki, H; Shimada, A; Watanabe, H; Yasui, N	1
Hayashi, T; Horii, N; Inoue, H; Kimura, J; Kunisaki, C; Maezawa, Y; Makino, H; Masuda, M; Ohnishi, H; Ohshima, T; Rino, Y; Suzuki, Y; Takagawa, R; Tsuburaya, A; Yamamoto, J	1
Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Legdeur, MC; Meulendijks, D; Schellens, JH	1
Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M	1
Baba, H; Baba, Y; Harada, K; Higashi, T; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Izumi, D; Kosumi, K; Miyamoto, Y; Miyata, T; Sakamoto, Y; Shiraishi, S; Taki, K; Tokunaga, R; Watanabe, M; Yamashita, Y; Yoshida, N	1
Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyanaga, S; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T	1
Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H	1
Doki, Y; Kurokawa, Y; Makino, T; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M; Yanagimoto, Y	1
Hayata, K; Iwahashi, M; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H	1
Cooray, P; Ferraro, DA; Ganju, V; Gebski, V; Hall, M; Pavlakis, N; Price, TJ; Shannon, JA; Sjoquist, KM; Strickland, A; Tebbutt, NC; Underhill, C; Varma, SC; Veillard, AS; Wong, N; Young, R	1
Hoshi, K; Hosoda, K; Katada, C; Katada, N; Koizumi, W; Mieno, H; Moriya, H; Watanabe, M; Yamashita, K	1
Matsuhashi, N; Miyazaki, T; Okumura, N; Tanahashi, T; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K	1
Fukuchi, M; Inose, T; Kato, H; Kuwano, H; Masuda, N; Miyazaki, T; Nakajima, M; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N	1
Hara, K; Honjo, H; Kuwano, H; Miyazaki, T; Ozawa, D; Sakai, M; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T	1
Qin, RQ; Wang, WP; Wen, YS; Xi, KX; Yu, XY; Zhang, LJ	1
Cheng, Y; Guan, S; Huang, X; Jia, Y; Ma, Y; Song, Q; Sun, Y; Tan, B; Wang, C; Wang, J; Yao, B	1
Hoshino, S; Iwasaki, K; Osaka, Y; Ota, Y; Suda, T; Tachibana, S; Tsuchida, A	1
Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y	1
Chikamatsu, S; Imai, H; Ishioka, C; Kasahara, Y; Kobayashi, A; Komine, K; Oishi, T; Okada, Y; Okita, A; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S	1
Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F	1
Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K	1
Abe, T; Hazama, S; Kanekiyo, S; Kitahara, M; Michihisa, I; Nagano, H; Nakajima, M; Nishiyama, M; Shindou, Y; Takeda, S; Yoshino, S	1
Aiba, K; Arakawa, Y; Ishibashi, Y; Matsumoto, A; Mitsumori, N; Nishikawa, K; Omura, N; Sakuyama, T; Tanaka, Y; Tanishima, Y; Yanaga, K; Yuda, M	1
Daiko, H; Doi, T; Fujii, S; Fujita, T; Hatogai, K; Kadota, T; Kojima, T; Ohtsu, A; Takiguchi, Y; Yoshino, T	1
Hayata, K; Katsuda, M; Nakamori, M; Nakamura, M; Nakamura, Y; Ojima, T; Yamaue, H	1
Guo, X; Hu, YH; Li, QQ; Liu, H; Liu, MZ; Liu, Q; Liu, SL; Luo, LL; Xi, M; Zhang, P; Zhao, L	1
Bando, H; Chin, K; Hamauchi, S; Hara, H; Honma, Y; Iwasa, S; Kato, K; Kii, T; Kiyota, N; Kojima, T; Mochizuki, S; Ohtsu, A; Satake, H; Tahara, M; Tsushima, T; Yamazaki, T; Yokota, T; Zenda, S	1
Al-Fakeeh, A; Al-Ruzug, I; Alcindor, T; Doerksen, T; Ferri, L; Mulla, N; Santos, F	1
Abramovich, A; Amit, L; Brenner, B; Gordon, N; Idelevich, E; Kundel, Y; Medalia, G; Purim, O; Sadeh Gonik, U; Sarfaty, M; Sulkes, A	1
Bonnetain, F; Borg, C; Cléau, D; Fein, F; Fiteni, F; Foubert, A; Fratté, S; Jacquin, M; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Mariette, C; Mathieu, P; Messager, M; Nguyen, T; Paget-Bailly, S; Sakek, N	1
Ambrosi, E; Casella, F; de Manzoni, G; Di Leo, A; Giacopuzzi, S; Motton, M; Ricci, F; Rice, TW; Vassiliadis, A; Verlato, G; Weindelmayer, J; Zanoni, A	1
Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N	1
Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T	1
Bitzer, M; Bösmüller, H; Clasen, S; Götz, M; Häussler, U; Malek, NP; Plentz, RR	1
Cho, H; Hayashi, T; Ikeda, K; Kano, K; Maezawa, Y; Masuda, M; Nakajima, T; Ogata, T; Ohshima, T; Rino, Y; Sato, T; Segami, K; Yamada, T; Yamamoto, N; Yoshikawa, T; Yukawa, N	1
Cheng, SY; Du, J; Li, J; Li, KC	1
Liang, N; Luo, H; Qiao, L; Xie, J; Yu, X; Zhang, J	1
Akutsu, Y; Asami, C; Chin, K; Hamamoto, Y; Hara, H; Hironaka, S; Ito, Y; Kato, K; Kawakami, K; Kii, T; Kitagawa, Y; Kojima, T; Kojima, Y; Matsushita, H; Mori, K; Nagai, Y; Ogawa, H; Tsubosa, Y; Ura, T; Yokota, T	1
Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Motoori, M; Shinkai, M; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T	1
Hosoda, K; Katada, C; Katada, N; Komori, S; Mieno, H; Moriya, H; Sugawara, M; Watanabe, M; Yamashita, K	1
Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R	1
Hatanaka, N; Hirao, T; Iwamoto, K; Kono, E; Mizuno, H; Morimoto, Y; Noro, H; Son, C; Takaichi, S; Yamasaki, Y; Yasumasa, K	1
Feng, X; Gao, C; Liu, L; Qu, D; Shi, F; Su, X; Wang, C	1
Aizawa, M; Bamba, T; Homma, K; Katsumi, C; Matsuki, A; Nakagawa, S; Yabusaki, H	1
Abou, M; Cacheux, W; Fernandez, E; Frossard, JL; Huber, O; Koessler, T; Moniez, M; Puppa, G; Roth, A	1
Cai, R; Dai, M; Diao, D; Ding, Y; Dong, X; Han, Z; Jia, C; Li, J; Shan, L; Su, Y; Wang, L; Xiong, G; Xu, W; Zheng, H; Zhou, L	1
Kitamura, S; Kuga, Y; Miwata, T; Mouri, T; Nishida, T; Sakimoto, H	1
Kajiyama, Y; Okumura, K; Okumura, M; Takeda, K; Tsurumaru, M	1
Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J	1
Ehara, K; Kinoshita, Y; Mine, S; Tsutsumi, K; Udagawa, H; Ueno, M	1
Kubo, A; Mitsui, Y; Nakahara, T; Shigematsu, N; Takagi, Y; Takemasa, K; Tsuyuki, A	1
Fujita, Y; Hiramatsu, M; Kawai, M; Nishimura, H; Sumiyoshi, K; Tanigawa, N	1
Fujii, Y; Harata, K; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Mori, Y; Ogawa, R; Tomoda, K	1
Nishimura, T; Oka, M; Takeda, S; Tokunou, K; Yoshino, S	1
Blaszkowsky, LS; Clark, JW; Earle, CC; Enzinger, PC; Fidias, P; Fuchs, CS; Kulke, MH; Mayer, RJ; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Vincitore, MM; Zhu, AX	1
Gennatas, C; Gennatas, S; Michalaki, V	1
Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S	1
Arai, H; Kobayashi, Y; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Nishi, Y; Sasajima, K; Sugiura, A; Suzuki, S; Tajiri, T; Wakabayashi, H; Yanagi, K; Yokoyama, T	1
BalmerMajno, S; Bodis, S; Borner, M; Hess, V; Köberle, D; Mingrone, W; Pestalozzi, BC; Popescu, R; Roth, A; Ruhstaller, T; Schnider, A; Schuller, JC; Terraciano, L; von Moos, R; Widmer, L	1
Cao, Z; Jin, J; Li, X; Liu, J; Lu, W; Tucker, SJ; Wang, D; Wang, F; Xu, X; Yan, G; Zhong, B	1
Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T	1
He, ZY; Hu, YH; Li, QQ; Lin, HX; Liu, H; Liu, MZ	1
Bae, SH; Baek, JH; Do, YR; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS	1
Artale, S; Bardelli, A; Barone, C; Cascinu, S; Di Fabio, F; Falcone, A; Giannetta, L; Giaquinta, S; Martoni, AA; Mutri, V; Pinto, C; Rojas Llimpe, FL; Schinzari, G; Siena, S; Stella, G	1
Arimura, Y; Hokari, K; Hosokawa, M; Kodaira, J; Okahara, S; Shinomura, Y; Takahashi, H; Tanuma, T; Tsukagoshi, H; Yamashita, K	1
Fujiwara, H; Ikoma, H; Kikuchi, S; Kokuba, Y; Kubota, T; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Sakakura, C; Sonoyama, T; Suchi, K; Todo, M; Umehara, S	1
Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kaida, Y; Kubota, H; Matsumoto, H; Murakami, H; Oka, Y; Okumura, H; Saito, A; Uragami, A; Yamashita, K; Yoden, E	1
Cummins, MM; Ganju, V; Gebski, V; Gibbs, D; Sourjina, T; Stockler, M; Strickland, A; Tebbutt, NC; Van Hazel, G; Zalcberg, J	1
Abbruzzese, JL; Ajani, J; Ho, L; Jhamb, J; Kazmi, SM; Lin, E; Overman, MJ; Phan, A; Yao, JC	1
Bae, WK; Cho, SB; Cho, SH; Chung, IJ; Hwang, JE; Joo, YE; Lee, WS; Na, KJ; Shim, HJ; Song, SY	1
Asaka, S; Ide, H; Isohata, N; Katsube, T; Konno, S; Murayama, M; Naritaka, Y; Ogawa, K; Shimakawa, T; Yamaguchi, K	1
Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY	1
Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E	1
Bauerfeind, P; Bertschinger, P; Binek, J; Brauchli, P; Frossard, JL; Jost, C; Knuchel, J; Metzger, U; Meyenberger, C; Ruhstaller, T; Schuller, JC; Werth, B	1
Burris, HA; Clark, BL; Farley, C; Gray, JR; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR	1
Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H	1
Andersen, M; Jensen, HA; Pfeiffer, P; Schønnemann, KR; Vestermark, LW; Yilmaz, M	1
Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M	1
Aggarwal, S; Goel, G; Jauhri, M; Negi, A	1
Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T	1
Allali, M; Bergmann, U; Kummer, G; Riebeling, J; Schultheis, B; Sendler, A; Sendler, U; Strumberg, D; Tannapfel, A	1
Hayashi, S; Karaki, H; Okaya, T; Sasaki, K; Sugano, I; Sugimoto, K; Suzuki, H; Yamamori, H; Yamamoto, K	1
Kito, F; Kunisaki, C; Matsuda, S; Mochizuki, Y; Takahashi, M; Watanabe, J; Yabuno, T	1
Ansari, RH; Choong, NW; Ferguson, MK; Fishkin, PA; Haraf, DC; Hoffman, PC; Kesler, KA; Kocherginsky, M; Krauss, SA; Mauer, AM; Posner, MC; Sandler, AB; Sciortino, DF; Szeto, L; Vokes, EE; Wade, J	1
Bernal, P; Byrd, J; Malik, I	1
Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M	1
Osada, S; Sanada, Y; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K	1
Arai, H; Hirakata, A; Kawamoto, M; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Umakoshi, M; Wakabayashi, H; Yokoyama, T	1
de Vries, A; Gastl, G; Lukas, P; Mühlmann, G; Öfner, D; Pluschnig, U; Spizzo, G; Steger, G; Widder, J; Zabernigg, A; Zacherl, J	1
Day, FL; Di Iulio, J; Jefford, M; Leong, T; Matera, A; McKendick, J; Michael, M; Milner, AD; Ngan, S; Rischin, D; Thomas, R; Zalcberg, JR	1
Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T	1
Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA	1
Brauchli, P; Dietrich, D; Gautschi, O; Hess, V; Inauen, R; Kranzbuehler, H; Mingrone, W; Montemurro, M; Moosmann, P; Pless, M; Rauch, D; Ruhstaller, T; Schneider, PM; von Moos, R; Widmer, L	1
Fujiwara, H; Furutani, A; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Shiozaki, A; Sonoyama, T; Todo, M; Umehara, S; Yoneda, M	1
Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Morimoto, J; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sakurai, K; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M	1
Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y	1
Kanemura, T; Kobayashi, M; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Ono, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Uchiyama, C; Yanai, A; Yoshioka, Y	1
Hamatsu, T; Hasegawa, H; Honboh, T; Kabashima, A; Kitamura, M; Kudo, K; Ninomiya, M; Ushijima, C	1
Ardalan, B; Avisar, E; Franceschi, D; Lima, M; Livingstone, A; Mezentsev, D; Podolsky, L; Reis, I; Rios, J; Solomon, N	1
Baba, H; Baba, Y; Hayashi, N; Hirashima, K; Hiyoshi, Y; Imamura, Y; Iwagami, S; Iwatsuki, M; Karashima, R; Kinoshita, K; Kurashige, J; Miyamoto, Y; Nagai, Y; Saito, S; Sato, N; Watanabe, M	1
Chun, CL; Dormady, S; Eisenstat, S; Lombard, C; Triadafilopoulos, G	1
Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S	1
Aoki, T; Hoshino, S; Ogata, T; Osaka, Y; Shinohara, M; Takagi, Y; Tsuchida, A	1
Ehara, K; Hasebe, S; Hayashi, M; Ito, T; Kinoshita, Y; Minowa, M; Ogawa, M; Takebayashi, K; Udagawa, H; Ueno, M	1
Arai, H; Hirakata, A; Kawamoto, M; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Umakoshi, M; Wakabayashi, H; Yokoyama, T; Yoshida, H	1
Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Hedman, H; Henriksson, R; Hesselius, P; Lennartsson, J; Wu, X	1
Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T	1
Cui, N; Hao, Y; Hu, Y; Liu, H; Liu, M; Lu, L; Mo, Y; Rong, T; Zhu, Q	1
Brugarolas, A; Pérez, T; Pérez-Ruixo, JJ; Rebollo, J; Valenzuela, B	1
Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J	1
Fan, X; Guo, B; Guo, W; Jiang, Y; Li, K; Liang, S; Qin, S; Wang, L; Wang, R; Zhao, Y	1
Lin, XD; Shi, XY; Zhang, WJ; Zhou, TC	1
Barthelemy, N; Chin, SH; Cunningham, JE; Falkowski, P; Kelechi, T; Sterba, K	1
Aizawa, T; Fujiwara, S; Harada, K; Kubo, N; Noguchi, T	1
Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T	1
Furukita, Y; Ikeda, M; Minato, T; Seike, J; Takashima, M; Takechi, H; Tangoku, A; Yamamoto, Y	1
Bonetti, A; Durante, E; Mercanti, A; Piacentini, P; Trolese, A	1
Bando, Y; Furukita, Y; Kajiura, K; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T	1
Abe, T; Hatooka, S; Kondo, C; Mizota, A; Muro, K; Nomura, M; Shinoda, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T	1
Bayraktar, S; Bayraktar, UD; Chen, E; Hosein, P; Koniaris, LG; Montero, AJ; Rocha-Lima, CM	1
Ades, S; Alcindor, T; Artho, G; Chasen, M; Ferri, LE; Hickeson, M; Marcus, V; Thirlwell, MP	1
Ariga, H; Jingu, K; Koto, M; Kubozono, M; Miyata, G; Narazaki, K; Nemoto, K; Onodera, K; Sugawara, T; Takeda, K; Umezawa, R; Yamada, S	1
Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T	1
Stravodimou, A; Voutsadakis, IA	1
Bechter, O; DE Vries, A; Eisterer, W; Kendler, D; Königsrainer, A; Lukas, P; Nehoda, H; Ofner, D; Spechtenhauser, B; Virgolini, I; Wöll, E	1
Osada, S; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K	1
Egawa, T; Eto, E; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Murakawa, M; Nagashima, A; Okamura, A	1
Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Yoneda, M	1
Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI	1
Akanuma, N; Akutsu, Y; Hoshino, I; Isozaki, Y; Kono, T; Matsubara, H; Miyazawa, Y; Shiratori, T; Shuto, K; Uesato, M	1
Hayashi, K; Kuramochi, H; Nakamura, T; Narumiya, K; Ota, M; Sato, T; Shirai, Y; Yamamoto, M	1
Aoki, Y; Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Okada, M	1
Chen, H; Zhang, T; Zhao, T	1
Aoki, T; Furukawa, H; Goto, Y; Imamoto, H; Imano, M; Kobayashi, K; Miki, H; Peng, YF; Takiuchi, H; Tamura, S; Tsujinaka, T	1
Hayakawa, T; Hirakata, A; Hosone, M; Katayama, H; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Takao, Y; Uchida, E; Umakoshi, M; Yokoyama, T; Yoshida, H	1
Cai, L; Guo, K; Hao, CL; Li, Z; Lin, P; Rong, TH; Wang, WP; Zhang, LJ; Zhang, Y; Zhu, JF	1
Haruma, K; Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M	1
Ellemann, AC; Kofoed, SC; Lundsgaard, M; Svendsen, LB	1
Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC	1
Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T	1
Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H	1
Bando, Y; Furukita, Y; Goto, M; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T; Yuasa, Y	1
Choi, SR; Han, JS; Hsing, CT; Jang, JS; Kim, DC; Roh, MH; Ryu, SH; Woo, SM	1
Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, DE; Na, KJ; Nam, TK; Shim, HJ	1
Baba, H; Baba, Y; Ishimoto, T; Iwatsuki, M; Kinoshita, K; Kurashige, J; Mimori, K; Nagai, Y; Saito, S; Watanabe, M	1
Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Hollerbach, S; Homann, N; Jäger, E; Kullmann, F; Luley, K; Mahlberg, R; Moehler, M; Pauligk, C; Prasnikar, N; Probst, S; Rethwisch, V; Stoehlmacher-Williams, J	1
Abd-Allah, D; El-Shazly, W; Khedr, G; Rostom, Y; Zaghloul, H	1
Bi, LW; Zhang, LZ; Zhao, HF	1
Capirci, C; Cordiano, C; de Manzoni, G; Grandinetti, A; Pasini, F; Pavarana, M; Rubello, D; Tomezzoli, A; Zanoni, A	1
Deguchi, K; Deguchi, T; Fukui, A; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Nomura, M; Omori, K; Takagi, M; Tamagawa, H; Tanaka, Y	1
Andoh, T; Arakawa, K; Itoh, H; Kobayashi, K; Sakamoto, K; Sato, H; Sunose, Y; Suto, Y; Takeyoshi, I; Tomizawa, N	1
Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E	1
Ades, S; Alcindor, T; Andalib, A; Artho, G; Chasen, M; Ferri, LE; Hickeson, M; Marcus, V; Thirlwell, MP	1
Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S	1
Abdel-Latif, RM; Anter, AH	1
Al-Batran, SE; Homann, N; Jäger, E; Lorenzen, S; Pauligk, C; Schmalenberg, H	1
Chen, X; Gao, Y; Hu, Z; Jiang, S; Liu, B; Liu, Y; Wu, Q; Zhang, X; Zhu, J	1
Bubis, JA; Dragnev, KH; Gordon, SR; Gui, J; Lisovsky, M; Rigas, JR; Sutton, JE; Wood, MD; Zaki, BI	1
Arnold, D; Brenner, B; Galle, PR; Gockel, I; Klautke, G; Lang, H; Moehler, M; Rödel, C; Roessler, HP; Schimanski, CC; Schmidberger, H; Thomaidis, T; Trarbach, T	1
Ajani, JA	2
Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F	1
Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT	1
Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V	1
Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C	1
Baker, SD; Faust, J; Govindan, R; Ma, MK; McLeod, HL; Perry, MC; Read, W; Trinkaus, K	1
Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H	1
Depisch, D; Hejna, M; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B	1
Boku, N; Chin, K; Fujita, H; Hamaguchi, T; Hyodo, I; Muro, K; Ohtsu, A; Ohtsu, T; Takiyama, W	1
Dempsey, DT; Furukawa, S; Gupta, D; McClurken, JB; Piacentino, V; Ross, K; Stepnowski, D	1
Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT	1
Hennequin, C	1
Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T	1
Bredenkamp, R; Duyster, J; Hennig, M; Lersch, C; Lordick, F; Lorenzen, S; Peschel, C; von Delius, S	1
Cetto, GL; Cordiano, C; de Manzoni, G; Durante, E; Gabbani, M; Grandinetti, A; Griso, C; Guglielmi, A; Maluta, S; Pasini, F; Pedrazzani, C; Pelosi, G; Tomezzoli, A	1
Bubis, JA; Dragnev, KH; Rigas, JR	1
Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY	1
Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E	1
Ebuchi, M; Hasegawa, K; Koide, A; Maruyama, M; Maruyama, S; Miyawaki, Y; Nagahama, T; Ohbu, M; Takashima, I; Tamura, N; Tanami, H	1
Ami, K; Ando, M; Nagahama, T; Ohbu, M	1
Andritzky, B; Boeters, I; Burkholder, I; Dürk, H; Edler, L; Görn, M; Horst, H; Hossfeld, DK; Laack, E; Lipp, R; Popp, J; Schuch, G	1
Brank, A; Camp, ER; Hochwald, SN; Li, J; Mackay, SL; Minnich, DJ	1
Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT	1
Endo, Y; Fujiwara, T; Hioki, M; Ikeda, Y; Kagawa, S; Kishimoto, H; Sakai, R; Tanaka, N; Urata, Y	1
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK	1
Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S	1
Fujita, F; Fujita, M; Shakuto, S	1
Asanuma, F; Atsuda, K; Etou, T; Hiraku, O; Masuda, A; Miyagawa, T; Morinaga, S; Osaku, M; Sasaki, K; Suzuki, T; Suzuki, Y; Tongu, M; Yamada, T; Yamada, Y	1
Fujiwara, S; Hori, T; Iiri, T; Kobayashi, Y; Morita, S; Nonaka, M; Saito, Y; Sugitani, S	1
Hashimoto, Y; Hayashidani, Y; Morifuji, M; Murakami, Y; Sudo, A; Sueda, T; Sugiyama, Y; Uemura, K	1
Ardalan, B; Franceschi, D; Hamilton-Nelson, K; Lima, M; Livingstone, A; Parra, J; Ribeiro, A	1
Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K	1
Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T	2
Aoki, T; Hoshino, S; Osaka, Y; Tachibana, S; Takagi, Y; Tsuchida, A	1
Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T	1
Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K	1
Ami, K; Ando, M; Ganno, H; Ito, T; Nagahama, T; Ohbu, M; Taira, M	1
Aoyama, N; Minamide, J; Oota, Y; Takada, K	1
Ancona, E; Boso, C; Chiarion-Sileni, V; Corti, L; Del Bianco, P; Innocente, R; Mazzarotto, R; Pigozzo, J; Ruol, A; Tomassi, O	1
Hashimoto, Y; Higashiyama, M; Inazawa, J; Ito, T; Kondo, K; Ortiz, C; Sakai, Y; Shimada, Y; Tanaka, E; Tsunoda, S	1
Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C	1
Abad, A; Arellano, A; Boix, J; Cardenal, J; Casas, D; Fernández-Llamazares, J; Font, A; Manzano, JL; Margelí, M; Rosell, R	1
Chao, KS	1
Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K	1
Chiba, T; Fukushima, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Mitsumori, M; Nishimura, T; Sakai, Y; Shimada, Y; Teramukai, S; Watanabe, G; Yanagihara, K; Yoshikawa, K	1
Fumoto, S; Kawahara, K; Noguchi, T; Shibata, T; Takahashi, Y; Takeno, S; Watanabe, S	1
Ilson, DH	1
Ajani, JA; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Marabotti, C; Moiseyenko, VM; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E	1
Ajani, JA; Awad, L; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Moiseyenko, VM; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E	1
Deeks, ED; Scott, LJ	1
Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H	1
Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K	1
Albertsson, M; Friesland, S; Frykholm, G; Johansson, B; Kadar, L; Letocha, H; Wagenius, G	1
Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H	1
Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M	1
Hayakawa, K; Higuchi, K; Ishiyama, H; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S	1
Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y	1
Ba-Ssalamah, A; Brodowicz, T; Hejna, M; Pluschnig, U; Püspök, A; Raderer, M; Schmidinger, M; Zacherl, J; Zielinski, CC	1
Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Inui, T; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yasui, H; Yoshino, T	1
Benson, AB; Einzig, AI; Karp, DD; Neuberg, D; O'Dwyer, PJ; Remick, SC; Stewart, JA	1
Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, SM	1
Haraf, DJ; Hoffman, PC; Mauer, AM; Vokes, EE	1
Choy, H	1
Law, S; Wong, J	1
Guillet, G; Karam, A; Labat, JP; Leroy, JP; Metges, JP	1
Forastiere, AA; Heath, EI; Marshall, J; Piantadosi, S; Urba, S	1

Reviews

21 review(s) available for docetaxel anhydrous and Cancer of Esophagus

Article	Year
Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma. Annals of surgical oncology, 2023, Volume: 30, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome	2023
Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2 Topics: Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Paclitaxel; Retrospective Studies; Taxoids	2023
FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet? Chinese clinical oncology, 2023, Volume: 12, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Stomach Neoplasms	2023
Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Scientific reports, 2019, 11-01, Volume: 9, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Esophageal Neoplasms; Humans; Perioperative Care; Stomach Neoplasms	2019
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. The Cochrane database of systematic reviews, 2020, 11-19, Volume: 11 Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms	2020
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2017, Volume: 35, Issue:12 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Ramucirumab; Stomach Neoplasms; Taxoids; Technology Assessment, Biomedical	2017
The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Current treatment options in oncology, 2017, 11-16, Volume: 18, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids	2017
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Fistula; Esophageal Neoplasms; Female; Humans; Oxonic Acid; Taxoids; Tegafur	2017
[A case of skeletal muscle metastasis on the left thigh after esophagectomy for esophageal adenocarcinoma in Barrett' s esophagus]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2015, Volume: 112, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Humans; Male; Middle Aged; Muscle, Skeletal; Recurrence; Taxoids	2015
[Adjuvant treatment for esophagogastric junction cancer]. Nihon Geka Gakkai zasshi, 2015, Volume: 116, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur	2015
The role of capecitabine in the management of tumors of the digestive system. Reviews on recent clinical trials, 2009, Volume: 4, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion, 2011, Volume: 83, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Taxoids	2011
Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:6 Suppl 6 Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Clinical Trials as Topic; Docetaxel; Esophageal Neoplasms; Humans; Paclitaxel; Stomach Neoplasms; Taxoids	2002
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. The Annals of thoracic surgery, 2004, Volume: 78, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2004
[Association of taxanes and radiotherapy: preclinical and clinical studies]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured	2004
Docetaxel in the treatment of esophageal cancer. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids	2005
Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Monitoring; Esophageal Neoplasms; Fluorouracil; Humans; Patient Selection; Stomach Neoplasms; Taxoids; Treatment Outcome	2006
Docetaxel: in gastric cancer. Drugs, 2007, Volume: 67, Issue:13 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Stomach Neoplasms; Taxoids	2007
Taxanes in combined-modality therapy for solid tumors. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids	1999
New adjuvant therapies for esophageal cancer. Advances in surgery, 2001, Volume: 35 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids	2001

Trials

153 trial(s) available for docetaxel anhydrous and Cancer of Esophagus

Article	Year
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Docetaxel; Esophageal Neoplasms; Humans; Japan	2022
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). ESMO open, 2021, Volume: 6, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Food, Formulated; Humans; Prospective Studies	2021
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-01, Volume: 40, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome	2022
A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 05-02, Volume: 28, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Radiation Dosage	2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 09-10, Volume: 40, Issue:26 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans	2022
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). BMC cancer, 2022, May-12, Volume: 22, Issue:1 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Stomach Neoplasms; Tumor Microenvironment	2022
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. BMJ open, 2022, 11-14, Volume: 12, Issue:11 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms	2022
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2 Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neoplasms; Treatment Outcome	2023
Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. Radiation oncology (London, England), 2023, Sep-12, Volume: 18, Issue:1 Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Follow-Up Studies; Humans; Prospective Studies	2023
Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Japanese journal of clinical oncology, 2019, Dec-18, Volume: 49, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Japan; Male; Middle Aged; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck	2019
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA oncology, 2019, 11-01, Volume: 5, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Proton Therapy; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome	2019
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer science, 2019, Volume: 110, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Prospective Studies	2019
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Treatment Outcome	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future oncology (London, England), 2020, Volume: 16, Issue:19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Nivolumab; Taxoids; Treatment Outcome; Young Adult	2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 12-10, Volume: 38, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Rate; Young Adult	2020
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08). Annals of surgery, 2022, 06-01, Volume: 275, Issue:6 Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Humans; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome	2022
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut, 2021, Volume: 70, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Female; Gossypol; Humans; Male; Mice; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms	2021
A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas. Medicine, 2021, Apr-30, Volume: 100, Issue:17 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Stomach Neoplasms; Survival Rate	2021
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nature communications, 2021, 06-29, Volume: 12, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome	2021
Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma. Oncology research, 2017, Sep-21, Volume: 25, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Postoperative Period; Radiotherapy, Intensity-Modulated; Survival Analysis; Taxoids	2017
Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. International journal of clinical oncology, 2018, Volume: 23, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed	2018
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 06-01, Volume: 29, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate	2018
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus. Oncology, 2018, Volume: 95, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Humans; Maximum Tolerated Dose; Oxonic Acid; Prospective Studies; Taxoids; Tegafur	2018
Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics, 2019, 10-01, Volume: 105, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Preoperative Period; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Remission Induction; ROC Curve; Sensitivity and Specificity; Survival Analysis; Treatment Outcome	2019
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World journal of surgical oncology, 2019, Jul-17, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Polyethylene Glycols; Prognosis; Retrospective Studies; Risk Factors; Survival Rate	2019
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Annals of surgical oncology, 2020, Volume: 27, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate	2020
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Camptothecin; Docetaxel; Drug Carriers; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nanocapsules; Stomach Neoplasms; Survival Rate; Taxoids	2013
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Humans; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids	2013
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome	2014
Phase II study of docetaxel (Aisu®) combined with three- dimensional conformal external beam radiotherapy in treating patients with inoperable esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:12 Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Conformal; Taxoids	2012
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex	2013
Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Japanese journal of clinical oncology, 2013, Volume: 43, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome	2013
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome; United States	2013
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome	2013
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer science, 2013, Volume: 104, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Thoracotomy; Treatment Outcome	2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2014
[A randomized controlled trial of intensity-modulated radiation therapy plus docetaxel and cisplatin versus simple intensity-modulated radiation therapy in II-III stage esophageal carcinoma]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2013, Volume: 16, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Prospective Studies; Radiography; Radiotherapy, Intensity-Modulated; Taxoids	2013
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids	2013
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2014
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Taxoids; Treatment Failure; Vomiting	2016
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet. Oncology, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids	2014
Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Panitumumab; Taxoids; Treatment Outcome	2014
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). International journal of radiation oncology, biology, physics, 2014, Jul-15, Volume: 89, Issue:4 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Taxoids	2014
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial. Anticancer research, 2014, Volume: 34, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur	2014
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer science, 2014, Volume: 105, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome	2014
Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:16 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Down-Regulation; Endostatins; Esophageal Neoplasms; Female; Humans; Male; Neovascularization, Pathologic; Radiography; Taxoids; Vascular Endothelial Growth Factor A	2014
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Turkey	2014
Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome	2015
Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome	2015
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Research Design; Survival Analysis; Taxoids; Treatment Outcome	2015
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. Annals of surgical oncology, 2015, Volume: 22, Issue:11 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome	2015
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids	2015
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World journal of gastroenterology, 2015, Apr-14, Volume: 21, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome	2015
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Young Adult	2015
[Clinical evaluations of neoadjuvant chemotherapy with DN and FP regimens for patients with middle or lower thoracic locally advanced esophageal squamous cell carcinoma]. Zhonghua yi xue za zhi, 2015, May-19, Volume: 95, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Rate; Taxoids	2015
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. International journal of radiation oncology, biology, physics, 2015, Oct-01, Volume: 93, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagitis; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Pneumonia; Radiotherapy Dosage; Stomatitis; Taxoids	2015
Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma. International surgery, 2015, Volume: 100, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Taxoids	2015
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Genetic Predisposition to Disease; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Stomach Neoplasms; Taxoids; Treatment Outcome	2015
Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clinical nutrition (Edinburgh, Scotland), 2017, Volume: 36, Issue:1 Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Cisplatin; Docetaxel; Endpoint Determination; Esophageal Neoplasms; Febrile Neutropenia; Feces; Female; Fluorouracil; Gastrointestinal Microbiome; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Neoadjuvant Therapy; Patient Compliance; Propionates; Prospective Studies; Serum Albumin; Synbiotics; Taxoids; Young Adult	2017
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, 02-01, Volume: 30, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Research Design; Taxoids; Treatment Outcome	2017
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus. Anticancer research, 2016, Volume: 36, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2016
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British journal of cancer, 2016, Mar-01, Volume: 114, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Fluorouracil; Humans; Infections; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Panitumumab; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting	2016
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. General thoracic and cardiovascular surgery, 2016, Volume: 64, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Epidemiologic Methods; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Taxoids; Treatment Outcome	2016
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids	2016
The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome	2016
Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer. Anticancer research, 2016, Volume: 36, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome	2016
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer science, 2016, Volume: 107, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Treatment Outcome	2016
Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer. Anticancer research, 2016, Volume: 36, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Treatment Outcome	2016
Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study. Anticancer research, 2016, Volume: 36, Issue:4 Topics: Abdomen; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Endoscopy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Thorax; Tomography, X-Ray Computed	2016
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome	2016
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Quality of Life; Stomach Neoplasms; Taxoids	2016
A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. PloS one, 2016, Volume: 11, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids	2016
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jan-01, Volume: 28, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome	2017
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. British journal of cancer, 2016, Nov-22, Volume: 115, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Rate; Taxoids	2016
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids	2008
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids	2009
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2009
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy; Taxoids; Treatment Outcome	2009
Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2010, Volume: 23, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome	2010
A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Neutropenia; Taxoids	2010
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British journal of cancer, 2009, Oct-20, Volume: 101, Issue:8 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids	2009
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Young Adult	2010
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British journal of cancer, 2010, Feb-02, Volume: 102, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids	2010
Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome	2010
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. Chinese journal of cancer, 2010, Volume: 29, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia	2010
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome	2010
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research Gastrointestinal endoscopy, 2010, Volume: 71, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Therapy, Combination; Endosonography; Esophageal Neoplasms; Esophagus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome	2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome; United States	2010
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology, 2010, Volume: 78, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Outpatients; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult	2010
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2010
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids	2010
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2010, Volume: 23, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Interactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome	2010
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Taxoids; Time Factors; Treatment Outcome	2011
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. Cancer investigation, 2010, Volume: 28, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Vomiting	2010
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome	2010
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. Annals of surgical oncology, 2011, Volume: 18, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Preoperative Care; Radiotherapy Dosage; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2011
Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. British journal of cancer, 2011, Jan-18, Volume: 104, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Taxoids	2011
[Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Cystic Fibrosis; Docetaxel; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Young Adult	2010
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-01, Volume: 29, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-20, Volume: 29, Issue:6 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Taxoids	2011
A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Floxuridine; Follow-Up Studies; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome	2011
Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer research, 2011, Volume: 31, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids	2011
[Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids	2011
[Intensity-modulated or 3-D conformal radiotherapy combined with chemotherapy with docetaxel and cisplatin for locally advanced esophageal carcinoma]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Radiotherapy, Conformal; Taxoids	2011
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology, 2011, Volume: 80, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Taxoids; Treatment Outcome	2011
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Perioperative Period; Stomach Neoplasms; Taxoids; Tumor Burden; Young Adult	2012
Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study. Anticancer research, 2011, Volume: 31, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome	2011
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study. Anticancer research, 2011, Volume: 31, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed	2011
A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepato-gastroenterology, 2012, Volume: 59, Issue:119 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Taxoids; Time Factors; Treatment Outcome	2012
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids	2012
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Taxoids	2012
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer research, 2012, Volume: 32, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids	2012
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2012
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British journal of cancer, 2012, Jul-24, Volume: 107, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids	2012
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome	2012
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Taxoids	2013
Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome. Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome	2013
Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase Cancer, 2013, Mar-01, Volume: 119, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids	2013
Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult	2013
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Radiotherapy, High-Energy; Remission Induction; Taxoids; Vomiting	2012
Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Prospective Studies; Taxoids	2013
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult	2013
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. British journal of cancer, 2013, Feb-19, Volume: 108, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Prognosis; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids	2013
Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. BMC cancer, 2013, Feb-11, Volume: 13 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Germany; Humans; Israel; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome	2013
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2003
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. International journal of gastrointestinal cancer, 2002, Volume: 32, Issue:2-3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting	2002
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2003
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Taxoids; Treatment Outcome	2003
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Oncology, 2003, Volume: 65, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Therapy, Combination; Erythropoietin; Esophageal Neoplasms; Esophagogastric Junction; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2003
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome	2004
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. British journal of cancer, 2005, Jun-20, Volume: 92, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2005
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids	2005
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2005
Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie, 2005, Volume: 28, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Germany; Humans; Lymphatic Metastasis; Male; Middle Aged; Pilot Projects; Prevalence; Taxoids; Treatment Outcome	2005
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-10, Volume: 24, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome	2006
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids	2006
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13 Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Radiotherapy Dosage; Radiotherapy, Adjuvant; Taxoids; Tegafur	2006
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Taxoids	2007
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. British journal of cancer, 2007, Feb-12, Volume: 96, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Taxoids	2007
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Comorbidity; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome	2007
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2007
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2007
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. American journal of clinical oncology, 2007, Volume: 30, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2007
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study. Cancer investigation, 2007, Volume: 25, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids	2007
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Treatment Outcome	2007
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein	2008
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 87, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Taxoids	2008
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Stud Anti-cancer drugs, 2008, Volume: 19, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Erythropoietin; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids	2008
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Medical oncology (Northwood, London, England), 1996, Volume: 13, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids	1996
Phase I study of docetaxel with concomitant thoracic radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Treatment Outcome	1998
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. Seminars in oncology, 1998, Volume: 25, Issue:3 Suppl 8 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids	1998
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids	2002

Other Studies

253 other study(ies) available for docetaxel anhydrous and Cancer of Esophagus

Article	Year
Study of the radiosensitization of docetaxel in human esophageal squamous carcinoma ECA109 cell line. Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:3(Special) Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; Radiation, Ionizing	2021
Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India. Journal of the Egyptian National Cancer Institute, 2021, Oct-21, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome	2021
Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers. BMC cancer, 2021, Oct-30, Volume: 21, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers, Tumor; Carboplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Nomograms; Support Vector Machine; Tomography, X-Ray Computed; Treatment Outcome	2021
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer. Investigational new drugs, 2022, Volume: 40, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neutropenia; Polymorphism, Genetic; Retrospective Studies	2022
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. BJS open, 2022, 01-06, Volume: 6, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Docetaxel; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms; Treatment Outcome	2022
Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome. Asian Pacific journal of cancer prevention : APJCP, 2022, Feb-01, Volume: 23, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Larynx; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Prognosis; Treatment Outcome	2022
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study. Anticancer research, 2022, Volume: 42, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrastim; Fluorouracil; Humans; Lymphoma, Follicular; Neutropenia; Polyethylene Glycols; Retrospective Studies	2022
Synergistic effects of BAY606583 on docetaxel in esophageal cancer through modulation of ERK1/2. Cell biochemistry and function, 2022, Volume: 40, Issue:6 Topics: Apoptosis; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; MAP Kinase Signaling System	2022
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter? Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms	2023
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. Anticancer research, 2022, Volume: 42, Issue:7 Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Translocation, Genetic	2022
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis. Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Propensity Score; Retrospective Studies; Taxoids	2022
Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. Annals of surgery, 2023, Jul-01, Volume: 278, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoadjuvant Therapy; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome	2023
Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Frontiers in public health, 2022, Volume: 10 Topics: Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Nivolumab; Paclitaxel	2022
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. Anticancer research, 2022, Volume: 42, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasms, Second Primary; Retrospective Studies; Taxoids; Treatment Outcome	2022
Single-Center Analysis of Pegfilgrastim-induced Aortitis Using a Drug Prescription Database and CT Findings. Radiology, 2022, Volume: 305, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aortitis; Breast Neoplasms; Cisplatin; Docetaxel; Drug Prescriptions; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Tomography, X-Ray Computed	2022
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer. Oncology, 2022, Volume: 100, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local	2022
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer. Anticancer research, 2022, Volume: 42, Issue:12 Topics: Aged; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Retrospective Studies	2022
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2 Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Taxoids	2023
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan. Annals of surgical oncology, 2023, Volume: 30, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Male; Neoadjuvant Therapy; Retrospective Studies; Taxoids	2023
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2 Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies	2023
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. Oncology, 2023, Volume: 101, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Retrospective Studies; Taxoids	2023
Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:3 Topics: Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; East Asian People; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Pneumonia; Postoperative Complications; Prognosis; Retrospective Studies	2023
Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study. Internal medicine (Tokyo, Japan), 2023, Volume: 62, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neutropenia; Retrospective Studies; Taxoids; Treatment Outcome	2023
Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023, Feb-04, Volume: 31, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Female; Fluorouracil; Humans; Male; Retrospective Studies	2023
Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective. Langenbeck's archives of surgery, 2023, Feb-10, Volume: 408, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Retrospective Studies; Stomach Neoplasms	2023
Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer. Anticancer research, 2023, Volume: 43, Issue:3 Topics: Aged; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Muscles; Neoadjuvant Therapy; Retrospective Studies; Risk Factors	2023
Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. General thoracic and cardiovascular surgery, 2023, Volume: 71, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Induction Chemotherapy; Treatment Outcome	2023
[A Case of Specific Pneumonia Diagnosed as Peritumoral Infiltration during Nivolumab Treatment for Esophageal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Pneumonia	2023
Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer. Anticancer research, 2023, Volume: 43, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Retrospective Studies	2023
The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. PloS one, 2023, Volume: 18, Issue:5 Topics: Antineoplastic Agents, Immunological; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Nutritional Status; Paclitaxel; Retrospective Studies	2023
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. Annals of surgical oncology, 2019, Volume: 26, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutition Disorders; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Survival Rate	2019
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery. Oncology, 2019, Volume: 97, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Prognosis	2019
Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. Journal of geriatric oncology, 2020, Volume: 11, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Retrospective Studies; Treatment Outcome	2020
[Preoperative Chemotherapy with DCF for Advanced Esophageal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Treatment Outcome	2019
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Lymph Nodes; Mediastinum; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur	2019
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer. Anti-cancer drugs, 2020, Volume: 31, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prospective Studies; Stomach Neoplasms	2020
Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. Esophagus : official journal of the Japan Esophageal Society, 2020, Volume: 17, Issue:2 Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Febrile Neutropenia; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vocal Cord Paralysis	2020
Metabolic response assessment and PET-guided treatment of esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:2 Topics: Adenocarcinoma; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Positron-Emission Tomography	2020
USP9X mRNA expression predicts clinical outcome for esophageal squamous cell carcinoma treated with cisplatin-based therapy. Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Radiotherapy, Adjuvant; RNA, Messenger; Ubiquitin Thiolesterase	2020
[A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Male; Neoadjuvant Therapy	2019
Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients. Esophagus : official journal of the Japan Esophageal Society, 2020, Volume: 17, Issue:4 Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Combined Modality Therapy; Creatinine; Docetaxel; Esophageal Neoplasms; Female; Humans; Incidence; Kidney Function Tests; Male; Neoplasm Staging; Radiotherapy; Retrospective Studies; Safety; Survival Rate	2020
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Molecular oncology, 2020, Volume: 14, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Azepines; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Hippo Signaling Pathway; Humans; Mice, Nude; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Transcription Factors; Transcription, Genetic; Triazoles; YAP-Signaling Proteins	2020
A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiation oncology (London, England), 2020, Apr-08, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Squamous Cell; Treatment Outcome; Young Adult	2020
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307). Annals of surgery, 2022, 04-01, Volume: 275, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Prognosis; Rad51 Recombinase; Treatment Outcome	2022
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience. Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Mucosa; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagoscopy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Retrospective Studies	2021
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma. Advances in therapy, 2020, Volume: 37, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; United States	2020
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Hospital Mortality; Humans; Length of Stay; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Postoperative Complications; Propensity Score; Survival Rate; Treatment Outcome	2020
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Survival Rate	2020
Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil. Annals of surgical oncology, 2021, Volume: 28, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Retrospective Studies; Treatment Outcome	2021
Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer. Anticancer research, 2020, Volume: 40, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Japan; Lymphatic Metastasis; Male; Middle Aged; Postoperative Complications; Prognosis; Treatment Outcome	2020
Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer. International journal of nanomedicine, 2020, Volume: 15 Topics: Animals; Antineoplastic Agents; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Esophageal Neoplasms; Humans; Hydrogen-Ion Concentration; Nanomedicine; Nanoparticles; Polyethylene Glycols; Polyethyleneimine; Tumor Microenvironment	2020
A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. Japanese journal of clinical oncology, 2021, Feb-08, Volume: 51, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils	2021
A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2021, Volume: 25, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Quinazolines; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Survival Rate; Thiophenes; Treatment Outcome	2021
ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma. Clinics and research in hepatology and gastroenterology, 2021, Volume: 45, Issue:5 Topics: Carcinogenesis; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans	2021
Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC). Clinical medicine & research, 2021, Volume: 19, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Stomach Neoplasms; Taxoids	2021
Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients. Chemotherapy, 2017, Volume: 62, Issue:3 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Esophageal Neoplasms; Female; Humans; Macula Lutea; Macular Edema; Male; Middle Aged; Ovarian Neoplasms; Taxoids; Tomography, Optical Coherence; Visual Acuity	2017
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. Chemotherapy, 2017, Volume: 62, Issue:4 Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Area Under Curve; Blood Platelets; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Platelet Count; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; ROC Curve; Taxoids	2017
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Japanese journal of clinical oncology, 2017, Aug-01, Volume: 47, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Rate; Taxoids	2017
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2017, Volume: 88, Issue:6 Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin	2017
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer. Anticancer research, 2017, Volume: 37, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Sarcopenia; Taxoids	2017
A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer. Acta pharmacologica Sinica, 2017, Volume: 38, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Compounding; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Humans; Nanostructures; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured	2017
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. Digestive surgery, 2018, Volume: 35, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids	2018
Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Surgical endoscopy, 2018, Volume: 32, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Rate; Thoracoscopy; Treatment Outcome	2018
Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy. Surgery, 2017, Volume: 162, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2017
Nano Let‑7b sensitization of eliminating esophageal cancer stem‑like cells is dependent on blockade of Wnt activation of symmetric division. International journal of oncology, 2017, Volume: 51, Issue:4 Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Male; MicroRNAs; Middle Aged; Nanomedicine; Neoplastic Stem Cells; Retinal Dehydrogenase; Retrospective Studies; RNA, Long Noncoding; Taxoids; Wnt Signaling Pathway	2017
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PloS one, 2017, Volume: 12, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Proto-Oncogene Mas; Taxoids; Treatment Outcome	2017
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2018, Apr-01, Volume: 31, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Propensity Score; Taxoids; Treatment Outcome	2018
Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil. Anticancer research, 2018, Volume: 38, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids	2018
[Case Report of an Acute Focal Bacterial Nephritis Associated with Adjuvant Chemotherapy in Esophageal Cancer Patient]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Middle Aged; Nephritis; Taxoids	2017
[A Case of Advanced Esophageal Cancer Successfully Treated with DCF Chemotherapy Followed by Conversion Surgery]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Taxoids; Treatment Outcome	2017
[A Case of Metachronous Resection for Advanced Esophageal Cancer with Pheochromocytoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Male; Pheochromocytoma; Taxoids	2017
[Outcome of Patients with Pathological Complete Response after Neoadjuvant Chemotherapy in Advanced Esophageal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome	2017
[A Case of Emergency Resection of Esophageal Cancer Which is on the Brink of Perforation after Neoadjuvant Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Emergency Medical Services; Esophageal Neoplasms; Esophageal Perforation; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids	2017
[Three-Year Survival after Lymphadenectomy for Residual Lymph Node Metastasis of Esophageal Cancer with Invasion into the Trachea and Carotid Artery after Chemoradiotherapy - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carotid Arteries; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Invasiveness; Taxoids; Trachea	2017
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Annals of surgical oncology, 2018, Volume: 25, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nomograms; Oxaliplatin; Positron Emission Tomography Computed Tomography; Preoperative Period; Radiopharmaceuticals; Radiotherapy Dosage; Risk Assessment; Sex Factors; Survival Rate	2018
Esophageal Metastases from Breast Carcinoma: a Rare Delayed Metastases After 15 Years. Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Docetaxel; Dose Fractionation, Radiation; Esophageal Mucosa; Esophageal Neoplasms; Esophagoscopy; Female; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Positron Emission Tomography Computed Tomography; Time Factors; Treatment Outcome	2019
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncology reports, 2018, Volume: 40, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Taxoids	2018
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. Esophagus : official journal of the Japan Esophageal Society, 2018, Volume: 15, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate	2018
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. World journal of surgical oncology, 2018, Jul-02, Volume: 16, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Prognosis; Retrospective Studies; Treatment Outcome	2018
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:7 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Chromones; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Delivery Systems; Drug Therapy, Combination; Esophageal Neoplasms; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanomedicine; Neoplasm Invasiveness; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study. Journal of surgical oncology, 2018, Volume: 118, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box-WD Repeat-Containing Protein 7; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies; Taxoids	2018
Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. Die Pharmazie, 2018, 10-01, Volume: 73, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Retrospective Studies	2018
[Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrastim; Fluorouracil; Humans; Neutropenia; Polyethylene Glycols; Prospective Studies; Retrospective Studies; Taxoids	2018
Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. Esophagus : official journal of the Japan Esophageal Society, 2019, Volume: 16, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cryotherapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Ice; Infusions, Intravenous; Male; Middle Aged; Quality of Life; Retrospective Studies; Stomatitis; Treatment Outcome	2019
Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. Cancer medicine, 2019, Volume: 8, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Platinum Compounds; Prognosis; Survival Analysis	2019
[A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Taxoids	2018
[Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrastim; Fluorouracil; Humans; Male; Polyethylene Glycols; Taxoids	2019
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma. World journal of surgery, 2019, Volume: 43, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Second Primary; Progression-Free Survival	2019
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy. The Annals of thoracic surgery, 2019, Volume: 108, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Contrast Media; Deglutition Disorders; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Perforation; Esophageal Stenosis; Esophagectomy; Fluorouracil; Follow-Up Studies; Humans; Male; Neoadjuvant Therapy; Risk Assessment; Stents; Tomography, X-Ray Computed; Treatment Outcome	2019
Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2020, Volume: 32, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagoscopy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome	2020
Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer. Medical oncology (Northwood, London, England), 2019, May-27, Volume: 36, Issue:7 Topics: Adult; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Case-Control Studies; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Prognosis; Programmed Cell Death 1 Receptor; Receptors, Virus	2019
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Esophagus : official journal of the Japan Esophageal Society, 2019, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Survival Rate	2019
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma. Asian journal of endoscopic surgery, 2020, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Operative Time; Retrospective Studies; Thoracoscopy; Treatment Outcome	2020
Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:4 Topics: Adult; Age Factors; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Male; Middle Aged; Neoadjuvant Therapy; Residence Characteristics; Retrospective Studies; Risk Factors	2020
[A case of far advanced-esophageal squamous cell carcinoma successfully treated with docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Taxoids	2013
Esophageal mucosal metastasis from adenocarcinoma of the distal stomach. World journal of gastroenterology, 2013, Jun-21, Volume: 19, Issue:23 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cisplatin; Disease Progression; Docetaxel; Endoscopy, Digestive System; Endosonography; Esophageal Neoplasms; Esophagus; Gastrectomy; Humans; Immunohistochemistry; Male; Middle Aged; Mucin 5AC; Mucous Membrane; Stomach Neoplasms; Taxoids; Treatment Outcome	2013
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Annals of surgical oncology, 2013, Volume: 20 Suppl 3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids	2013
[Pathological complete response in a case of advanced esophageal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Taxoids	2013
[A case of advanced esophagogastric junction cancer responding to pre-operative combination chemotherapy of docetaxel, cisplatin, S-1, and trastuzumab]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Middle Aged; Taxoids; Trastuzumab	2013
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy. Anticancer research, 2013, Volume: 33, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids	2013
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma. The Lancet. Oncology, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Stomach Neoplasms; Taxoids	2014
[Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids	2013
[A case of liver metastasis from esophageal cancer treated with stereotactic body radiation therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Organoplatinum Compounds; Recurrence; Taxoids; Treatment Outcome; Whole-Body Irradiation	2013
[Study of decreased oral intake in patients receiving neoadjuvant chemotherapy for esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Eating; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Taxoids	2013
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report. Journal of gastrointestinal cancer, 2014, Volume: 45 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids	2014
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. American journal of clinical oncology, 2016, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Proportional Hazards Models; Retrospective Studies; Taxoids	2016
Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology, 2014, Volume: 146, Issue:7 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cisplatin; Docetaxel; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptide Initiation Factors; Proportional Hazards Models; Protein Binding; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Taxoids; Time Factors; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Annals of surgical oncology, 2014, Volume: 21, Issue:9 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Taxoids	2014
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome	2014
Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. Annals of surgical oncology, 2014, Volume: 21, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Survival Rate; Taxoids	2014
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? Journal of surgical oncology, 2014, Volume: 110, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms	2014
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Annals of surgical oncology, 2015, Volume: 22, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids	2015
Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids	2014
High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:9 Topics: Adult; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Taxoids; Young Adult	2014
Antitumor Efficacy of Docetaxel-loaded Nanocarrier against Esophageal Cancer Cell Bearing Mice Model. Drug research, 2015, Volume: 65, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chitosan; Docetaxel; Drug Carriers; Drug Delivery Systems; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Male; Mice; Mice, Nude; Nanoparticles; Taxoids	2015
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Annals of surgery, 2015, Volume: 262, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoadjuvant Therapy; Neoplasm Staging; Shoulder; Survival Rate; Taxoids	2015
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2014
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? Annals of surgical oncology, 2015, Volume: 22, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutition Disorders; Docetaxel; Enteral Nutrition; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Taxoids	2015
Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma. Anticancer research, 2015, Volume: 35, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2015
Effectiveness of proton beam therapy on liver metastases of esophageal cancer: report of a case. International surgery, 2015, Volume: 100, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Proton Therapy; Radiography; Taxoids	2015
[Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recurrence; Taxoids	2014
Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer. The Annals of thoracic surgery, 2015, Volume: 99, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Care; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2015
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma. BMC cancer, 2015, Apr-30, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Esophageal Neoplasms; Female; Gene Expression; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Transport Proteins; Middle Aged; Precision Medicine; Prognosis; Response Evaluation Criteria in Solid Tumors; RNA, Messenger; ROC Curve; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1	2015
Engineering Stent Based Delivery System for Esophageal Cancer Using Docetaxel. Molecular pharmaceutics, 2015, Jul-06, Volume: 12, Issue:7 Topics: Animals; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Esophageal Neoplasms; Esophagus; Polymers; Stents; Swine; Taxoids	2015
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Taxoids	2015
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer? Annals of surgical oncology, 2016, Volume: 23, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine	2016
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2015
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. British journal of cancer, 2015, Sep-15, Volume: 113, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Male; MAP Kinase Kinase Kinases; Middle Aged; Neoplasm Proteins; Radiation Tolerance; RNA, Messenger; ROC Curve; Taxoids; Ubiquitin-Protein Ligases; Zearalenone	2015
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Paclitaxel; Peptide Initiation Factors; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Taxoids	2015
The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial. PharmacoEconomics, 2016, Volume: 34, Issue:1 Topics: Adenocarcinoma; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Gastrointestinal Neoplasms; Health Care Costs; Humans; Quality-Adjusted Life Years; Taxoids	2016
[Complete Response in Far-Advanced Esophageal Cancer Treated with Induction Chemotherapy Followed by Definitive Chemoradiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Taxoids	2015
[A Case of Resected Gastric Cancer Invading the Esophagus with Esophageal Recurrence That Responded to Weekly Docetaxel／Cisplatin Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Recurrence; Stomach Neoplasms; Taxoids; Treatment Outcome	2015
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Journal of gastroenterology, 2016, Volume: 51, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome	2016
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells. International journal of oncology, 2016, Volume: 48, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; DNA Breaks, Double-Stranded; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids	2016
Plasma ghrelin levels as a predictor of adverse renal events due to cisplatin-based chemotherapy in patients with esophageal cancer. Japanese journal of clinical oncology, 2016, Volume: 46, Issue:5 Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Ghrelin; Humans; Male; Middle Aged; Severity of Illness Index; Taxoids	2016
Planned Esophagectomy after Neoadjuvant Hyperthermo-Chemoradiotherapy using Weekly Low-Dose Docetaxel and Hyperthermia for Advanced Esophageal Carcinomas. Hepato-gastroenterology, 2015, Volume: 62, Issue:140 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagitis; Female; Humans; Hyperthermia, Induced; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome	2015
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma. Hepato-gastroenterology, 2015, Volume: 62, Issue:140 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome	2015
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. Annals of surgical oncology, 2016, Volume: 23, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur	2016
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Feb-01, Volume: 30, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Endoscopy, Digestive System; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Retrospective Studies; Taxoids; Treatment Outcome	2017
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma. Chemotherapy, 2016, Volume: 61, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome	2016
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2016, Volume: 32, Issue:5 Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Microwaves; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Ultrasonography	2016
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Journal of surgical oncology, 2016, Volume: 113, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Prognosis; Retrospective Studies; Survival Analysis; Taxoids	2016
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surgery today, 2017, Volume: 47, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression; Genetic Association Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids	2017
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis. Oncotarget, 2016, Jul-12, Volume: 7, Issue:28 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Pneumonia; Propensity Score; Taxoids; Thrombocytopenia	2016
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; France; Humans; Male; Middle Aged; Propensity Score; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2017
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer. Annals of surgical oncology, 2016, Volume: 23, Issue:Suppl 5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids	2016
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World journal of surgery, 2017, Volume: 41, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Taxoids; Tumor Suppressor Protein p53	2017
AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime). Zeitschrift fur Gastroenterologie, 2016, Volume: 54, Issue:10 Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Taxoids; Treatment Outcome	2016
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrectomy; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur	2016
[Second-line treatment for metastatic or locally advanced gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Oct-23, Volume: 38, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids	2016
[Concurrent chemoradiotherapy followed by docetaxel and cisplatin consolidation chemotherapy in elderly patients with esophageal carcinoma]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2016, Oct-28, Volume: 41, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagitis; Female; Hematologic Diseases; Humans; Male; Radiotherapy, Intensity-Modulated; Remission Induction; Taxoids	2016
Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer. Oncology, 2017, Volume: 92, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Postoperative Complications; Taxoids	2017
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence. Oncology, 2017, Volume: 92, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Preoperative Care; Prognosis; Prospective Studies; Taxoids; Treatment Outcome	2017
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Parenteral Nutrition; Taxoids	2016
[Pathological Complete Response in a Case of Advanced Esophageal Cancer with Widespread Lymph Node Metastases Treated Using Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-FU(DCF therapy)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Taxoids	2016
A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance. Drug delivery, 2017, Volume: 24, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cyclooctanes; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Esophageal Neoplasms; Humans; Inhibitory Concentration 50; Lignans; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polycyclic Compounds; Solubility; Surface Properties; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays	2017
[Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Recurrence; Taxoids; Time Factors; Treatment Outcome	2017
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Period; Preoperative Period; Retrospective Studies; Stomach Neoplasms; Surgical Procedures, Operative; Survival Analysis; Switzerland; Taxoids; Young Adult	2017
Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma. Experimental cell research, 2017, 04-01, Volume: 353, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Survivin; Taxoids	2017
[A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Taxoids; Treatment Outcome	2017
Correlation between loss of Bcl-XL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2008, Volume: 41, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Caspase 3; Caspase 8; Chemotherapy, Adjuvant; Combined Modality Therapy; DNA Primers; Docetaxel; Esophageal Neoplasms; Fas-Associated Death Domain Protein; Female; Gene Expression; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids	2008
[A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagoscopes; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed	2008
Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis. European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:10 Topics: Acute Disease; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Fluorodeoxyglucose F18; Hepatitis; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Taxoids	2008
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2008, Volume: 21, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Probability; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2008
Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma. Oncology reports, 2008, Volume: 20, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Integrin beta1; Models, Biological; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Taxoids	2008
[A case of esophageal cancer patient who developed tumor lysis syndrome after chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Taxoids; Tomography, X-Ray Computed; Tumor Lysis Syndrome	2008
[A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagoscopy; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Male; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Remission Induction; Taxoids; Tomography, X-Ray Computed	2009
Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2009
[A case of the oldest old patient with advanced esophageal cancer responding completely to the combination chemotherapy of docetaxel/5-fluorouracil/nedaplatin with radiation]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:7 Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Organoplatinum Compounds; Taxoids	2009
[PSK-mediated growth suppression and enhancement of 5-FU/docetaxel-induced cytotoxicity in human esophageal cancer cell lines]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Proteoglycans; Taxoids	2009
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Oxonic Acid; Taxoids; Tegafur	2009
Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer, 2010, Mar-15, Volume: 116, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids	2010
A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy). Anticancer research, 2010, Volume: 30, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Taxoids	2010
[An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:5 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deglutition; Docetaxel; Esophageal Neoplasms; Fatal Outcome; Humans; Male; Myocardial Infarction; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quality of Life; Renal Dialysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2010
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids	2010
[A case of advanced esophageal cancer with no recurrence treated biweekly with postoperative docetaxel/nedaplatin combined chemotherapy after non-curative surgery]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Neoplasm Staging; Organoplatinum Compounds; Remission Induction; Taxoids	2010
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagoscopy; Gastroscopy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed	2010
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2011
[A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, nedaplatin and 5-fluorouracil]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatal Outcome; Fluorouracil; Humans; Male; Neoplasm Staging; Organoplatinum Compounds; Stomach Neoplasms; Taxoids	2010
[Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; C-Reactive Protein; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Taxoids; Treatment Outcome	2010
[Docetaxel with concurrent radiotherapy in patients with inoperable or relapsed oesophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids	2010
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Remission Induction; Stents; Taxoids; Trachea; Tracheal Neoplasms; Tracheal Stenosis	2010
[Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Taxoids	2010
[A case successfully treated with subtotal esophagectomy after preoperative second-line chemotherapy for cT4 esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Male; Taxoids	2010
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue. Digestive diseases and sciences, 2011, Volume: 56, Issue:7 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Antineoplastic Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Esophageal Achalasia; Esophageal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Intestinal Polyposis; Liver Neoplasms; Male; Neoplastic Syndromes, Hereditary; Peritoneal Neoplasms; Proton Pump Inhibitors; Taxoids; Trastuzumab	2011
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2011
[A case of advanced esophageal carcinoma with nephrotic syndrome completely responding to chemotherapy of docetaxel, nedaplatin and 5-fluorouracil]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Staging; Nephrotic Syndrome; Organoplatinum Compounds; Remission Induction; Taxoids; Tomography, X-Ray Computed	2011
Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; Docetaxel; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Membrane Glycoproteins; Membrane Proteins; Middle Aged; Neoplasm Proteins; Prognosis; Survival Rate; Sweden; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2012
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. International journal of cancer, 2012, Apr-01, Volume: 130, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Remission Induction; Stomach Neoplasms; Taxoids; Treatment Outcome	2012
Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 99, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoplasm Staging; Prognosis; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Taxoids	2011
Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report. British journal of clinical pharmacology, 2011, Volume: 72, Issue:6 Topics: Antineoplastic Agents; Beverages; Carcinoma, Squamous Cell; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Esophageal Neoplasms; Female; Food-Drug Interactions; Humans; Middle Aged; Taxoids	2011
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC cancer, 2011, Jun-24, Volume: 11 Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome	2011
Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib. Clinical science (London, England : 1979), 2012, Volume: 122, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Docetaxel; Drug Synergism; Esophageal Neoplasms; Female; Humans; Mad2 Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Repressor Proteins; src-Family Kinases; Taxoids; Thiazoles; Up-Regulation; Xenograft Model Antitumor Assays	2012
Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Male; Massage; Middle Aged; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Quality of Life; Taxoids	2011
[Complete response in a patient with liver metastasis of esophageal squamous cell carcinoma treated with docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:7 Topics: Aged; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Taxoids; Tomography, X-Ray Computed	2011
[A case of a patient with stage IVa esophageal cancer surviving over 4 years by combination chemotherapy with docetaxel,5 -FU and cisplatin, without operation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed	2011
Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2012, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2012
Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Annals of surgical oncology, 2012, Volume: 19, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; ErbB Receptors; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Taxoids; Tumor Suppressor Protein p53	2012
Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer research, 2011, Volume: 31, Issue:10 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Postoperative Complications; Recurrence; Retrospective Studies; Taxoids; Treatment Outcome	2011
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2012
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer. International journal of radiation oncology, biology, physics, 2012, May-01, Volume: 83, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Japan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids	2012
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology, 2011, Volume: 81, Issue:3-4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids	2011
Hand and foot syndrome associated with docetaxel treatment. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Taxoids; Treatment Outcome	2012
[Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recurrence; Retrospective Studies; Salvage Therapy; Taxoids	2011
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed	2011
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed	2012
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Taxoids; Tegafur	2012
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Stomach Neoplasms; Taxoids	2012
The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chinese journal of cancer, 2012, Volume: 31, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids	2012
A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma. Anticancer research, 2012, Volume: 32, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids	2012
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function. Danish medical journal, 2012, Volume: 59, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabine; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Deglutition Disorders; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Perforation; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prosthesis Failure; Retrospective Studies; Stents; Taxoids	2012
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. Surgery today, 2013, Volume: 43, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Taxoids; Time Factors	2013
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Annals of surgical oncology, 2013, Volume: 20, Issue:1 Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hyaluronan Receptors; Isoenzymes; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Proportional Hazards Models; Retinal Dehydrogenase; Retrospective Studies; Taxoids	2013
A case of synchronous esophagus and stomach cancer successfully treated by combined chemotherapy. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2012, Volume: 60, Issue:2 Topics: Aged, 80 and over; Antineoplastic Agents; Cisplatin; Docetaxel; Drug Therapy, Combination; Endoscopy, Digestive System; Esophageal Neoplasms; Humans; Male; Positron-Emission Tomography; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed	2012
RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. British journal of cancer, 2012, Oct-09, Volume: 107, Issue:8 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Hexosyltransferases; Humans; Male; Neoadjuvant Therapy; Proteasome Endopeptidase Complex; Taxoids	2012
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Taxoids; Vomiting	2012
[Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Taxoids	2012
[A case of Barrett's esophageal carcinoma treated with combined therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids	2012
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Annals of surgical oncology, 2013, Volume: 20, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Hospitals, High-Volume; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome	2013
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PloS one, 2013, Volume: 8, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids	2013
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Thoracic Neoplasms; Tomography, X-Ray Computed	2013
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer, 2003, Aug-01, Volume: 98, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas	2003
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prognosis; Taxoids	2003
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax. The Annals of thoracic surgery, 2004, Volume: 78, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Humans; Ligation; Male; Middle Aged; Neoplasm Metastasis; Parenteral Nutrition, Total; Peritoneovenous Shunt; Pleural Effusion; Postoperative Complications; Respiration, Artificial; Taxoids; Thoracostomy; Thoracotomy; Tissue Adhesives	2004
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids	2005
High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Taxoids; Treatment Outcome	2005
[The docetaxel radiosensitization experience for the treatment of unresectable esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11 Topics: Aged; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids	2005
[Weekly docetaxel in combination with concomitant radiotherapy for esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids	2005
Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. The Journal of surgical research, 2006, Volume: 132, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorouracil; Genes, Reporter; Humans; Kinetics; Luciferases; NF-kappa B; Taxoids	2006
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. International journal of cancer, 2006, Jul-15, Volume: 119, Issue:2 Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Docetaxel; Drug Carriers; Esophageal Neoplasms; Feasibility Studies; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Polymerase Chain Reaction; Stomach Neoplasms; Taxoids; Telomerase; Transplantation, Heterologous; Vinblastine; Vinorelbine	2006
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation. Oncology reports, 2006, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays	2006
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous	2006
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oxonic Acid; Pyridines; Succinate Dehydrogenase; Taxoids; Tegafur; Thymidylate Synthase; Tumor Cells, Cultured	2006
[A case of recurrent esophageal cancer with lung metastases successfully treated with docetaxel-combination chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Remission Induction; Taxoids; Tomography, X-Ray Computed	2006
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Oxonic Acid; Pyridines; Taxoids; Tegafur	2006
Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. The American journal of gastroenterology, 2006, Volume: 101, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Endosonography; Esophageal Neoplasms; Female; Floxuridine; Humans; Leucovorin; Lymph Nodes; Male; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids	2006
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Quality of Life; Remission Induction; Taxoids; Tegafur	2006
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. The journal of medical investigation : JMI, 2006, Volume: 53, Issue:3-4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Taxoids; Tegafur	2006
Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2006, Volume: 19, Issue:6 Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids	2006
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. International journal of clinical oncology, 2006, Volume: 11, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Remission Induction; Salvage Therapy; Taxoids	2006
[A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids	2006
The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4 Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays	2007
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. Journal of surgical oncology, 2007, Mar-01, Volume: 95, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Taxoids; Trachea	2007
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer. Seminars in oncology, 2007, Volume: 34, Issue:2 Suppl 1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome	2007
[A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids	2007
Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. International journal of clinical oncology, 2007, Volume: 12, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids	2007
[A case of recurrent esophageal cancer successfully treated with concurrent radiochemotherapy with low-dose docetaxel plus 5-FU]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Remission Induction; Taxoids	2007
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome	2007
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Quality of Health Care; Taxoids; Tegafur; Uracil	2007
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy, 2007, Volume: 53, Issue:6 Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2007
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Gastroscopy; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed	2008
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. International journal of clinical oncology, 2008, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vindesine	2008
Squamous syringometaplasia associated with docetaxel. The British journal of dermatology, 2002, Volume: 146, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Metaplasia; Middle Aged; Necrosis; Paclitaxel; Sweat Gland Neoplasms; Sweat Glands; Taxoids	2002